Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677577 | 1.00 | PDE5A (0.50) | PDE5AMIFRIPK1CYP19A1LMNA | |
| SCHEMBL85419 | 0.83 | TSHR (0.56) | PDE5ARIPK1CYP19A1LMNAKDM4E | |
| SCHEMBL1006162 | 0.81 | TSHR (0.55) | PDE5ARIPK1CYP19A1LMNAKDM4E | |
| SCHEMBL30598386 | 0.79 | KDM4E (0.53) | MIFLMNAKDM4EMEN1KMT2A | |
| SCHEMBL3394300 | 0.79 | NPC1 (0.54) | MIFLMNAKDM4EMEN1KMT2A | |
| SCHEMBL28426349 | 0.79 | KDM4E (0.45) | MIFLMNAKDM4EMEN1KMT2A | |
| SCHEMBL1089189 | 0.79 | ALDH1A1 (0.55) | MIFLMNAKDM4EMEN1KMT2A | |
| SCHEMBL7825882 | 0.78 | KDM4E (0.55) | LMNAKDM4EMEN1KMT2ATSHR | |
| SCHEMBL10299988 | 0.78 | TSHR (0.50) | PDE5ARIPK1CYP19A1LMNAKDM4E | |
| Phosphine SCHEMBL22320255 | 0.76 | KDM4E (0.41) | MIFLMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-11530212-B2 | Fluorescent probe compound for zinc ion, as well as preparation method and use thereof | WUYI UNIVERSITY (CN) | 2022-12-20 | — | — | US | claimed |
| US-20210393597-A1 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | US | claimed |
| US-20210347847-A1 | THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-11-11 | — | — | US | claimed |
| CN-113398271-A | Novel anti-infection strategy against influenza virus and staphylococcus aureus co-infection | 归属疗法有限公司 | 2021-09-17 | — | — | CN | claimed |
| US-20210147412-A1 | A FLUORESCENT PROBE COMPOUND FOR ZINC ION, AS WELL AS PREPARATION METHOD AND USE THEREOF | DONGLI TEST (GUANGDONG) GO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| US-20200390786-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-17 | — | — | US | claimed |
| US-20200368282-A1 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS | THE GENERAL HOSPITAL CORPORATION | 2020-11-26 | — | — | US | claimed |
| WO-2020228640-A1 | ZINC ION FLUORESCENT PROBE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 五邑大学 | 2020-11-19 | — | — | WO | claimed |
| US-20200230135-A1 | ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTIONAL MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-23 | — | — | US | claimed |
| US-20150366909-A1 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS | THE GENERAL HOSPITAL CORPORATION | 2015-12-24 | — | — | US | claimed |
| EP-2953634-A1 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS | The General Hospital Corporation (US) | 2015-12-16 | — | — | EP | claimed |
| WO-2015173788-A1 | NOVEL ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-19 | — | — | WO | claimed |
| US-20150297598-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-10-22 | — | — | US | claimed |
| US-20150232856-A1 | TELOMERASE INHIBITORS FOR USE IN THERAPY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-08-20 | — | — | US | claimed |
| EP-2900229-A1 | TELOMERASE INHIBITORS FOR USE IN THERAPY | Agency For Science, Technology And Research (SG) | 2015-08-05 | — | — | EP | claimed |
| WO-2014124134-A1 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-08-14 | — | — | WO | claimed |
| WO-2014085154-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-06-05 | — | — | WO | claimed |
| US-20110144043-A1 | Stat modulators | DANA-FARBER CANCER INSTITUTE (US) | 2011-06-16 | — | — | US | claimed |
| WO-2008156644-A2 | STAT MODULATORS | FRANK DAVID A (US) | 2008-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390786-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | SLC11A2, BRCA1, RNASE1 | PDE5A 3893/4885MIF 4509/4885RIPK1 2553/4885 |
| US-20110144043-A1 | Stat modulators | STAT1, STAT5A, STAT5B | PDE5A 775/4885MIF 435/4885RIPK1 742/4885 |
| US-20210347847-A1 | THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS | CD47, CD74, HAVCR2 | PDE5A 4065/4885MIF 1708/4885RIPK1 1209/4885 |
| US-20150297598-A1 | METHODS FOR TREATING RENAL DISEASE | LDLR, APOL1, APOB | PDE5A 2977/4885MIF 3132/4885RIPK1 817/4885 |
| US-11530212-B2 | Fluorescent probe compound for zinc ion, as well as preparation method and use thereof | SLC30A7, SLC39A7, SLC30A6 | PDE5A 4447/4885MIF 3143/4885RIPK1 2934/4885 |
| US-20210147412-A1 | A FLUORESCENT PROBE COMPOUND FOR ZINC ION, AS WELL AS PREPARATION METHOD AND USE THEREOF | SLC30A7, SLC30A6, SLC39A7 | PDE5A 4414/4885MIF 2883/4885RIPK1 2641/4885 |
| US-20150232856-A1 | TELOMERASE INHIBITORS FOR USE IN THERAPY | TERT, TERF2, POT1 | PDE5A 1222/4885MIF 730/4885RIPK1 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.